Low-risk prostate cancer well managed with active surveillance

"There are far more people presenting to us for care than we have people able to provide it. The APPs are going to be a critical part of trying to solve that puzzle," says Mark T. Edney, MD.

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

The European approval of Illuccix adds on to prior approvals in the US, Australia, and Canada.

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

In total, 40.3% of patients experienced a change in staging between initial assessment on conventional imaging and PSMA PET.

The planned sBLA will seek approval of Anktiva for patients with BCG-unresponsive NMIBC in the papillary indication.